Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Madeleine Duvic, MD, Joseph D Khoury, MD, Keyur Patel, MD, Naval Daver, MD, Susan O'Brien, MD, Sherry Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Elias Jabbour, Nitin Jain, MD, Stefan Faderl, MD, Deborah Thomas, MD, Arthur E. Frankel, MD, Muzaffar H. Qazilbash, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 3746.

https://doi.org/10.1182/blood.V126.23.3746.3746

Published: 2015

Journal Articles

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Blood (2015) 126 (23): 323.

https://doi.org/10.1182/blood.V126.23.323.323

Published: 2015

Journal Articles

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

Delettre Fanny, PhD, Arthur E. Frankel, MD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Eric Deconninck, MD, Francis Bonnefoy, PhD, Baptiste Lamarthee, PhD Student, Christopher L. Brooks, PhD, Eric Rowinsky, MD, Philippe Saas, Ph.D., Francine Garnache Ottou, PhD

Blood (2013) 122 (21): 3942.

https://doi.org/10.1182/blood.V122.21.3942.3942

Published: 2013

Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 2682.

https://doi.org/10.1182/blood.V122.21.2682.2682

Published: 2013

Journal Articles

An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL

Arthur E. Frankel, MD, Jung H Woo, PhD, Jeremy P Mauldin, PhD, Francine M. Foss, MD, Madeleine Duvic, MD, David M Neville, Jr., MD

Blood (2013) 122 (21): 4381.

https://doi.org/10.1182/blood.V122.21.4381.4381

Published: 2013

Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD

Blood (2012) 120 (21): 3625.

https://doi.org/10.1182/blood.V120.21.3625.3625

Published: 2012

Journal Articles

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

Fanny Angelot-Delettre, PhD, Arthur E. Frankel, MD, Jen Sing Liu, PhD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Bernard Drenou, MD, PhD, Mark L. Jacobson, MA, Thomas P. Cirrito, PhD, Arkam Yazid, MD, Eric Deconinck, MD, PhD, Christopher L. Brooks, PhD, Philippe Saas, PhD, Francine Garnache Ottou, PhD

Blood (2011) 118 (21): 2588.

https://doi.org/10.1182/blood.V118.21.2588.2588

Published: 2011

Journal Articles

IL3R Directed Agents, SL-401 and SL-501, Inhibit the Growth of Leukemia Stem Cells In CML.

Olga Frolova, MD, PhD, Arthur E Frankel, MD, Borys Korchin, MD, PhD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD, Ph.D., Marina Konopleva, MD, PhD

Blood (2010) 116 (21): 3403.

https://doi.org/10.1182/blood.V116.21.3403.3403

Published: 2010

Journal Articles

Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS

Blood (2010) 116 (21): 3298.

https://doi.org/10.1182/blood.V116.21.3298.3298

Published: 2010

Journal Articles

Targeting IL3 Receptor in Chronic Myeloid Leukemia.

Olga Frolova, MD, PhD, Rui-Yu Wang, MD, PhD, Borys Korchin, Julie C. Watt, Jorge Cortes, MD, Arthur E. Frankel, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD

Blood (2009) 114 (22): 2172.

https://doi.org/10.1182/blood.V114.22.2172.2172

Published: 2009

Journal Articles

Phase I Study Demonstrates Activity and Tolerability of Diphtheria Toxin Interleukin-3 Fusion Protein in Patients with AML and MDS.

Arthur E. Frankel, MD, E.R. Smith, T.A. George, J.S. Liu, PhD, J. Lee, S.K. Park, MD, David A. Rizzieri, MD, Donna E. Hogge, MD

Blood (2007) 110 (11): 894.

https://doi.org/10.1182/blood.V110.11.894.894

Published: 2007

Journal Articles

A Phase II Study of Denileukin Diftitox (ONTAK R ) in Patients with Fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia.

Philip Kuriakose, MD, Francesco Turturro, MD, Jesus G. Berdeja, MD, Robert Kerr, MD, Asha Surendranathan, Jennifer Black, Arthur E. Frankel, MD

Blood (2004) 104 (11): 4824.

https://doi.org/10.1182/blood.V104.11.4824.4824

Published: 2004

Journal Articles

Variant Forms of Human Interleukin-3 (IL-3) Linked to Truncated Diphtheria Toxin (DT 388 ), Have Enhanced Cytotoxicity Against Acute Myeloid Leukemia (AML) Progenitors.

Siaw Hui Wong, Arthur E. Frankel, MD, Donna E. Hogge, MD,Ph.D

Blood (2004) 104 (11): 1797.

https://doi.org/10.1182/blood.V104.11.1797.1797

Published: 2004

NARROW

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

IL3R Directed Agents, SL-401 and SL-501, Inhibit the Growth of Leukemia Stem Cells In CML.

Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS

Targeting IL3 Receptor in Chronic Myeloid Leukemia.

Phase I Study Demonstrates Activity and Tolerability of Diphtheria Toxin Interleukin-3 Fusion Protein in Patients with AML and MDS.

A Phase II Study of Denileukin Diftitox (ONTAK R ) in Patients with Fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia.

Variant Forms of Human Interleukin-3 (IL-3) Linked to Truncated Diphtheria Toxin (DT 388 ), Have Enhanced Cytotoxicity Against Acute Myeloid Leukemia (AML) Progenitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only